Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.16.2 (
PCP
)
3,761
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
To understand the processes involved in the catalytic mechanism of
pyridoxal kinase
(
PLK
),1 we determined the crystal structures of
PLK
.AMP-
PCP
-pyridoxamine,
PLK
.ADP.PLP, and
PLK
.ADP complexes. Comparisons of these structures have revealed that
PLK
exhibits different conformations during its catalytic process. After the binding of AMP-
PCP
(an analogue that replaced ATP) and pyridoxamine to
PLK
, this enzyme retains a conformation similar to that of the
PLK
.ATP complex. The distance between the reacting groups of the two substrates is 5.8 A apart, indicating that the position of ATP is not favorable to spontaneous transfer of its phosphate group. However, the structure of
PLK
.ADP.PLP complex exhibited significant changes in both the conformation of the enzyme and the location of the ligands at the active site. Therefore, it appears that after binding of both substrates, the enzyme-substrate complex requires changes in the protein structure to enable the transfer of the phosphate group from ATP to vitamin B(6). Furthermore, a conformation of the enzyme-substrate complex before the transition state of the enzymatic reaction was also hypothesized.
...
PMID:Conformational changes in the reaction of pyridoxal kinase. 1472 69